12 West Capital Management LP Sells 5,642 Shares of Repligen Corporation $RGEN

Key Points

• 12 West Capital Management LP reduced its stake in Repligen Corporation by 2.3%, owning approximately 241,233 shares valued at about $30.7 million, making it the firm's 6th largest holding.
• Repligen's shares have seen price adjustments, with several analysts changing their ratings and price targets, including a downgrade from buy to hold by Wall Street Zen.
• Despite a missed EPS estimate of $0.37 for the most recent quarter, Repligen reported a revenue increase of 14.8% year-over-year, totaling $182.37 million.

12 West Capital Management LP decreased its stake in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) by 2.3% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 241,233 shares of the biotechnology company's stock after selling 5,642 shares during the period. Repligen comprises about 4.5% of 12 West Capital Management LP's investment portfolio, making the stock its 6th biggest holding. 12 West Capital Management LP owned about 0.43% of Repligen worth $30,694,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of RGEN. Raiffeisen Bank International AG acquired a new position in Repligen in the fourth quarter worth $29,000. Twin Tree Management LP acquired a new position in Repligen in the first quarter worth $29,000. Signaturefd LLC boosted its holdings in Repligen by 65.3% in the first quarter. Signaturefd LLC now owns 324 shares of the biotechnology company's stock worth $41,000 after purchasing an additional 128 shares during the period. Center for Financial Planning Inc. boosted its holdings in Repligen by 110.3% in the first quarter. Center for Financial Planning Inc. now owns 368 shares of the biotechnology company's stock worth $47,000 after purchasing an additional 193 shares during the period. Finally, UMB Bank n.a. boosted its holdings in Repligen by 99.4% in the first quarter. UMB Bank n.a. now owns 666 shares of the biotechnology company's stock worth $85,000 after purchasing an additional 332 shares during the period. Institutional investors own 97.64% of the company's stock.

Insider Buying and Selling

In related news, Director Martin D. Madaus bought 1,800 shares of the stock in a transaction on Friday, August 8th. The shares were purchased at an average price of $112.13 per share, with a total value of $201,834.00. Following the purchase, the director owned 1,800 shares in the company, valued at approximately $201,834. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 1.20% of the company's stock.

Analyst Ratings Changes

RGEN has been the subject of a number of research reports. HC Wainwright reaffirmed a "buy" rating and issued a $180.00 price objective on shares of Repligen in a report on Wednesday. Wall Street Zen downgraded shares of Repligen from a "buy" rating to a "hold" rating in a report on Sunday, June 29th. Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $205.00 price objective on shares of Repligen in a report on Tuesday. Wells Fargo & Company dropped their target price on Repligen from $180.00 to $175.00 and set an "overweight" rating on the stock in a research report on Wednesday, July 30th. Finally, Evercore ISI dropped their target price on Repligen from $140.00 to $130.00 and set an "in-line" rating on the stock in a research report on Tuesday, July 8th. Eight analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $169.55.

Repligen Stock Performance

RGEN stock traded up $3.98 during trading on Friday, reaching $124.56. 1,043,994 shares of the company's stock were exchanged, compared to its average volume of 653,843. The company has a quick ratio of 7.32, a current ratio of 8.59 and a debt-to-equity ratio of 0.26. Repligen Corporation has a 1-year low of $102.96 and a 1-year high of $182.52. The company's fifty day moving average price is $121.53 and its 200-day moving average price is $129.29. The firm has a market cap of $7.01 billion, a PE ratio of -498.22, a P/E/G ratio of 2.29 and a beta of 1.07.

Repligen (NASDAQ:RGEN - Get Free Report) last released its earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 EPS for the quarter, missing the consensus estimate of $0.40 by ($0.03). The company had revenue of $182.37 million for the quarter, compared to analyst estimates of $174.62 million. Repligen had a negative net margin of 2.05% and a positive return on equity of 4.61%. The firm's quarterly revenue was up 14.8% on a year-over-year basis. During the same period in the previous year, the business posted $0.40 EPS. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. On average, research analysts expect that Repligen Corporation will post 1.72 EPS for the current fiscal year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.